A committee from the European Medicines Agency (EMA) has voted against granting Leqembi (lecanemab) a marketing authorization due to the risk of serious side effects associated with the treatment.
Vaxxinity has announced the publication of its phase 2 clinical trial data for UB-311, stating that the treatment was safe, well-tolerated and demonstrated a trend for slowing cognitive decline in mild Alzheimer's disease (AD).
Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose portion of the phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment...
Axol Bioscience Ltd, a pluripotent stem cell technology provider for drug discovery, has signed an exclusive agreement with StrataStem to access and commercialize its extensive collection of Alzheimer’s Disease (AD) patient samples.
The antibody drug donanemab, developed by the pharma giant Eli Lilly, has met all of its goals in a phase 3 trial for slowing cognitive decline in people with Alzheimer’s disease.
Eisai has submitted marketing authorization applications for lecanemab in Europe and Japan as it builds up its global plans for the Alzheimer’s drug, which was approved in the US earlier this month.
On Friday (Jan 6), the US Food and Drink Administration (FDA) granted a licence for another anti-amyloid drug – lecanemab – to treat Alzheimer’s disease.
Roche announced yesterday that Phase 3 studies for its Alzheimer’s drug gantenerumab failed to meet the primary endpoint of slowing clinical decline. Although disappointed, Alzheimer’s associations are hopeful there is still a lot that can be learned...
The WHO has set out a new blueprint for dementia research: outlining the potential of precision medicine, repurposed drugs and revamped clinical trials. “Addressing dementia is one of the greatest health challenges of our generation,” says the organization.
Biogen will ‘substantially eliminate’ commercial infrastructure for Alzheimer’s drug Aduhelm and take additional cost-reduction measures, the company announced as it released its Q1 2022 results this morning.
Biogen has estimated 10 million patients in the US are suitable for treatment with its Alzheimer’s disease candidate aducanumab, setting it up to generate blockbuster sales if it wins approval.
